<< Read Full Article
<< Read Full Article
Dendreon's Date With Destiny
- Loading Comments...
Updated from March 8
Dendreon(DNDN Quote) will take its prostate cancer drug Provenge in front of an FDA advisory panel on March 29. This is going to be a major stock-moving event, and for me, at least, the outcome is very much in the air.
I said as much in a column last week, but I also promised to dig deeper into the story. Having done so, here's a discussion of the issues surrounding Provenge's date with the FDA.
What is Provenge? ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,479.66 | 1,110.06 | 2,179.06 | 32.55 |
Oil *
79.45
|
|
UP
134.82
|
UP
14.43
|
UP
34.46
|
UP
0.54
|
10 Yr
3.25%
SPDR Gold
117.44
|
|
+1.30%
|
+1.32%
|
+1.61%
|
+1.69%
|
Data delayed 20 minutes |


Connect with TheStreet